Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells-Reference-Cited by-同舟云学术

Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

Published:2020-03-25 Issue:4 Volume:98 Page:355-367
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Nini Alessandro¹²^ORCID,Hoffmann Michèle Janine¹^ORCID,Lampignano Rita³,große Siemer Robert¹,Dalum Guus⁴,Szarvas Tibor⁵⁶,Cotarelo Cristina Lopez⁷,Schulz Wolfgang Arthur¹,Niederacher Dieter³⁸,Neubauer Hans³⁸,Stoecklein Nikolas Hendrik⁴⁸,Niegisch Günter¹^ORCID

Affiliation:

1. Department of Urology, Medical Faculty University Hospital of the Heinrich‐Heine‐University Duesseldorf Duesseldorf Germany

2. Department of Urology Saarland University Homburg/Saar Germany

3. Department of Gynecology and Obstetrics, Medical Faculty University Hospital of the Heinrich‐Heine‐University Duesseldorf Duesseldorf Germany

4. Department of General, Visceral and Pediatric Surgery, Medical Faculty University Hospital of the Heinrich‐Heine‐University Duesseldorf Duesseldorf Germany

5. Department of Urology, Medical Faculty University of Duisburg‐Essen Essen Germany

6. Department of Urology Semmelweis University Budapest Budapest Hungary

7. Department of Pathology, Medical Faculty University Hospital of the Heinrich‐Heine‐University Duesseldorf Duesseldorf Germany

8. Disseminated Cancer Cell Network (DCCNet) Duesseldorf Heinrich‐Heine‐University Duesseldorf Germany

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21877

Reference52 articles.

1. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system

2. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder

3. Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM

4. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

5. Comprehensive molecular characterization of urothelial bladder carcinoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

2. Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis;Frontiers in Oncology;2024-03-14

3. EpCAM tumor specificity and proteoform patterns in urothelial cancer;Journal of Cancer Research and Clinical Oncology;2023-05-08

4. The Glucose-Regulated Protein78 (GRP78) in the Unfolded Protein Response (UPR) Pathway: A Potential Therapeutic Target for Breast Cancer;Anti-Cancer Agents in Medicinal Chemistry;2023-03

5. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role;International Journal of Molecular Sciences;2023-02-13